{
    "clinical_study": {
        "@rank": "5006", 
        "arm_group": [
            {
                "arm_group_label": "N-acetylcysteine", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in the  N-acetylcysteine group receive 600 mg non-effervescent N-acetylcysteine tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material."
            }, 
            {
                "arm_group_label": "Theophylline", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in the Theophylline group receive 200 mg Theophylline slow-release tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material."
            }, 
            {
                "arm_group_label": "Theophylline plus N-acetylcysteine", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in the Theophylline plus N-acetylcysteine group receive Theophylline  slow-release 200 mg tablet plus non-effervescent N-acetylcysteine 600 mg tablet twice daily from 24 hours before to 48 hours after administration of contrast material."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to determine the efficacy of Theophylline, N-Acetylcysteine and,\n      and Theophylline plus N-acetylcysteine in the prevention of contrast-induced nephropathy.\n      Investigators assume that Theophylline plus N-acetylcysteine is more effective than\n      Theophylline alone and N-acetylcysteine alone. Investigators include patients referring for\n      elective coronary angiography or angioplasty and allocate them to each of the mentioned\n      treatments from 24 hours before to 48 hours after administration of contrast material.\n      Investigators then measure serum creatinine and see if it is raised by \u2265 0.5 mg/dL or \u2265 25%\n      of the baseline value."
        }, 
        "brief_title": "Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy", 
        "condition": "Contrast-Induced Nephropathy", 
        "condition_browse": {
            "mesh_term": "Kidney Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients\n\n          -  candidate of elective coronary angiography or angioplasty\n\n          -  at least moderate risk for contrast induced nephropathy\n\n        Exclusion Criteria:\n\n          -  unstable angina or myocardial infarction, cardiac arrhythmia, seizures, acute renal\n             failure, end-stage renal disease\n\n          -  unstable serum creatinine\n\n          -  unstable hemodynamic\n\n          -  intravascular administration of contrast material in the past month\n\n          -  using theophylline or  N-acetylcysteine in the past month,\n\n          -  known hypersensitivity to theophylline or  N-acetylcysteine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088502", 
            "org_study_id": "392300"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "N-acetylcysteine", 
                    "Theophylline plus N-acetylcysteine"
                ], 
                "intervention_name": "N-acetylcysteine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Theophylline", 
                    "Theophylline plus N-acetylcysteine"
                ], 
                "intervention_name": "Theophylline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "N-acetylcysteine", 
                    "Theophylline", 
                    "Theophylline plus N-acetylcysteine"
                ], 
                "description": "All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.", 
                "intervention_name": "0.9% sodium chloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine", 
                "Theophylline"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Coronary Angiography", 
            "Side Effects", 
            "Contrast-Induced Nephropathy", 
            "Prevention"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "drmortezaarabmomeni@gmail.com", 
                "last_name": "Mortaza Arabmomeni, M.D.", 
                "phone": "09131268466"
            }, 
            "facility": {
                "address": {
                    "city": "Isfahan", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Chamran Hospital"
            }, 
            "investigator": {
                "last_name": "Mortaza Arabmomeni, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparative Evaluation of the Effect of Theophylline Plus N-acetylcysteine, Theophylline Alone, and N-acetylcysteine Alone in Preventing Contrast-induced Nephropathy in Patients With Moderate to High Risk Undergoing Coronary Angiographic Procedures", 
        "overall_contact": {
            "email": "drmortezaarabmomeni@gmail.com", 
            "last_name": "Mortaza Arabmomeni, M.D.", 
            "phone": "09131268466"
        }, 
        "overall_official": {
            "affiliation": "Isfahan University of Medical Sciences", 
            "last_name": "Mortaza Arabmomeni, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Plasma creatinine level is measured at baseline and after 48 hours of contrast injection. Increase in plasma creatinine level \u2265 0.5 mg/dL or \u2265 25% of the baseline creatinine after 48 hours of contrast injection will be considered contrast induced nephropathy.", 
            "measure": "Plasma creatinine level", 
            "safety_issue": "No", 
            "time_frame": "up to 48h after contrast injection"
        }, 
        "reference": {
            "PMID": "22994682", 
            "citation": "Albabtain MA, Almasood A, Alshurafah H, Alamri H, Tamim H. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study. J Interv Cardiol. 2013 Feb;26(1):90-6. doi: 10.1111/j.1540-8183.2012.00767.x. Epub 2012 Sep 20."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088502"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Isfahan University of Medical Sciences", 
            "investigator_full_name": "Mortaza Arabmomeni", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Isfahan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isfahan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}